Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 11, 2013, Pages 1933-1938

  Chen, Yao ^a,b   Zhang, Wei ^a   Huang, Wei Hua ^a   Tan, Zhi Rong ^a   Wang, Yi Cheng ^a   Huang, Xi ^b   Zhou, Hong Hao ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Drug drug interaction; OATP1B1; Pitavastatin; Rifampin

Indexed keywords

PITAVASTATIN; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; ORGANIC ANION TRANSPORTERS; QUINOLINES; RIFAMPIN; YOUNG ADULT;

EID: 84886799677     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1554-0     Document Type: Article

References (29)

1. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342-350
2. Saito Y (2011) Pitavastatin: An overview. Atheroscler Suppl 12:271-276
3. Hu M, Mak VW, Yin OQ, Chu TT, Tomlinson B (2012) Effects of grapefruit juice and SLCO1B1 388A > G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet
4. Choi CI, Lee YJ, Lee HI, Kim BH, Kim MJ, Jang CG, Bae JW, Lee SY (2012) Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. Xenobiotica 42:496-501
5. Anderson MS, Cote J, Liu Y, Stypinski D, Auger P, Hohnstein A, Rasmussen S, Johnson-Levonas AO, Gutstein DE (2013) Effects of rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of Anacetrapib. J Clin Pharmacol
6. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS (2011) Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: Considerations on drug-drug interactions. Biopharm Drug Dispos 32:175-184
7. Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, Chen WS (2012) SLCO1B1*15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep 6:75-82
8. Frymoyer A, Shugarts S, Browne M, Wu AH, Frassetto L, Benet LZ (2010) Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther 88:540-547
9. Bruderer S, Aanismaa P, Homery MC, Hausler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J (2012) Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 14:68-78
10. Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M (2012) The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemother Pharmacol 69:1247-1253
11. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
12. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD (2012) Complex drug interactions of the HIV protease inhibitors 3: Effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 40:610-616
13. Abdel Halim M, Al-Otaibi T, Gheith O, El-Kholy O, Abdel Tawab K, Said T, Nair P, Nampoory MR (2010) Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. Ann Transplant 15:57-60
14. Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions: An update. Arch Intern Med 162:985-992
15. Baciewicz AM, Chrisman CR, Finch CK, Self TH (2013) Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29:1-12
16. Lam JL, Shugarts SB, Okochi H, Benet LZ (2006) Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319:864-870
17. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB (2002) Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 72:524-535
18. Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W (2004) CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 75:213-222
19. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK (2008) Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52:772-779
20. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121
21. Kim KA, Park PW, Liu KH, Kim KB, Lee HJ, Shin JG, Park JY (2008) Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 48:66-72
22. Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y (2006) Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 80:509-521
23. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W (2006) Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 80:477-485
24. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-547
25. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG (2008) The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424-433
26. Oh ES, Kim CO, Cho SK, Park MS, Chung JY (2012) Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet
27. Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S (2013) CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie 68:187-194
28. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y (2013) Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966-974
29. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581